Tissue | Expression Dynamics | Abbreviation |
Breast | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Breast/PAK2_pca_on_diff_genes.png) | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/PAK2_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/PAK2_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/PAK2_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/PAK2_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/PAK2_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/PAK2_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/PAK2_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/PAK2_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00480101 | Oral cavity | NEOLP | vascular endothelial growth factor receptor signaling pathway | 16/2005 | 59/18723 | 3.48e-04 | 3.36e-03 | 16 |
GO:000276422 | Oral cavity | NEOLP | immune response-regulating signaling pathway | 74/2005 | 468/18723 | 3.90e-04 | 3.63e-03 | 74 |
GO:00182122 | Oral cavity | NEOLP | peptidyl-tyrosine modification | 62/2005 | 378/18723 | 4.27e-04 | 3.91e-03 | 62 |
GO:004586024 | Oral cavity | NEOLP | positive regulation of protein kinase activity | 63/2005 | 386/18723 | 4.41e-04 | 3.99e-03 | 63 |
GO:005149417 | Oral cavity | NEOLP | negative regulation of cytoskeleton organization | 32/2005 | 163/18723 | 5.07e-04 | 4.48e-03 | 32 |
GO:00181082 | Oral cavity | NEOLP | peptidyl-tyrosine phosphorylation | 61/2005 | 375/18723 | 5.88e-04 | 5.08e-03 | 61 |
GO:003223125 | Oral cavity | NEOLP | regulation of actin filament bundle assembly | 23/2005 | 105/18723 | 6.28e-04 | 5.38e-03 | 23 |
GO:001063932 | Oral cavity | NEOLP | negative regulation of organelle organization | 57/2005 | 348/18723 | 7.37e-04 | 6.03e-03 | 57 |
GO:015010516 | Oral cavity | NEOLP | protein localization to cell-cell junction | 8/2005 | 21/18723 | 9.62e-04 | 7.39e-03 | 8 |
GO:003134922 | Oral cavity | NEOLP | positive regulation of defense response | 47/2005 | 278/18723 | 1.05e-03 | 7.99e-03 | 47 |
GO:00343329 | Oral cavity | NEOLP | adherens junction organization | 13/2005 | 49/18723 | 1.52e-03 | 1.07e-02 | 13 |
GO:003367423 | Oral cavity | NEOLP | positive regulation of kinase activity | 70/2005 | 467/18723 | 2.33e-03 | 1.50e-02 | 70 |
GO:012019310 | Oral cavity | NEOLP | tight junction organization | 17/2005 | 80/18723 | 4.25e-03 | 2.40e-02 | 17 |
GO:003433311 | Oral cavity | NEOLP | adherens junction assembly | 5/2005 | 12/18723 | 5.81e-03 | 3.04e-02 | 5 |
GO:000283311 | Oral cavity | NEOLP | positive regulation of response to biotic stimulus | 29/2005 | 168/18723 | 6.52e-03 | 3.34e-02 | 29 |
GO:000221831 | Oral cavity | NEOLP | activation of innate immune response | 12/2005 | 52/18723 | 7.72e-03 | 3.84e-02 | 12 |
GO:00507302 | Oral cavity | NEOLP | regulation of peptidyl-tyrosine phosphorylation | 41/2005 | 264/18723 | 9.51e-03 | 4.50e-02 | 41 |
GO:000225313 | Oral cavity | NEOLP | activation of immune response | 55/2005 | 375/18723 | 9.87e-03 | 4.62e-02 | 55 |
GO:200123318 | Prostate | BPH | regulation of apoptotic signaling pathway | 134/3107 | 356/18723 | 5.06e-22 | 7.84e-19 | 134 |
GO:190290318 | Prostate | BPH | regulation of supramolecular fiber organization | 133/3107 | 383/18723 | 2.40e-18 | 8.73e-16 | 133 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0513024 | Breast | IDC | Pathogenic Escherichia coli infection | 42/867 | 197/8465 | 2.66e-06 | 3.92e-05 | 2.94e-05 | 42 |
hsa0481014 | Breast | IDC | Regulation of actin cytoskeleton | 36/867 | 229/8465 | 5.79e-03 | 3.13e-02 | 2.34e-02 | 36 |
hsa045109 | Breast | IDC | Focal adhesion | 32/867 | 203/8465 | 8.60e-03 | 4.23e-02 | 3.17e-02 | 32 |
hsa052118 | Breast | IDC | Renal cell carcinoma | 14/867 | 69/8465 | 9.16e-03 | 4.37e-02 | 3.27e-02 | 14 |
hsa0517014 | Breast | IDC | Human immunodeficiency virus 1 infection | 33/867 | 212/8465 | 9.28e-03 | 4.37e-02 | 3.27e-02 | 33 |
hsa0513034 | Breast | IDC | Pathogenic Escherichia coli infection | 42/867 | 197/8465 | 2.66e-06 | 3.92e-05 | 2.94e-05 | 42 |
hsa0481015 | Breast | IDC | Regulation of actin cytoskeleton | 36/867 | 229/8465 | 5.79e-03 | 3.13e-02 | 2.34e-02 | 36 |
hsa0451013 | Breast | IDC | Focal adhesion | 32/867 | 203/8465 | 8.60e-03 | 4.23e-02 | 3.17e-02 | 32 |
hsa0521113 | Breast | IDC | Renal cell carcinoma | 14/867 | 69/8465 | 9.16e-03 | 4.37e-02 | 3.27e-02 | 14 |
hsa0517015 | Breast | IDC | Human immunodeficiency virus 1 infection | 33/867 | 212/8465 | 9.28e-03 | 4.37e-02 | 3.27e-02 | 33 |
hsa0513043 | Breast | DCIS | Pathogenic Escherichia coli infection | 42/846 | 197/8465 | 1.40e-06 | 2.15e-05 | 1.59e-05 | 42 |
hsa0517024 | Breast | DCIS | Human immunodeficiency virus 1 infection | 33/846 | 212/8465 | 6.49e-03 | 3.22e-02 | 2.37e-02 | 33 |
hsa0481023 | Breast | DCIS | Regulation of actin cytoskeleton | 35/846 | 229/8465 | 6.89e-03 | 3.37e-02 | 2.48e-02 | 35 |
hsa0521123 | Breast | DCIS | Renal cell carcinoma | 14/846 | 69/8465 | 7.42e-03 | 3.48e-02 | 2.56e-02 | 14 |
hsa0513053 | Breast | DCIS | Pathogenic Escherichia coli infection | 42/846 | 197/8465 | 1.40e-06 | 2.15e-05 | 1.59e-05 | 42 |
hsa0517034 | Breast | DCIS | Human immunodeficiency virus 1 infection | 33/846 | 212/8465 | 6.49e-03 | 3.22e-02 | 2.37e-02 | 33 |
hsa0481033 | Breast | DCIS | Regulation of actin cytoskeleton | 35/846 | 229/8465 | 6.89e-03 | 3.37e-02 | 2.48e-02 | 35 |
hsa0521133 | Breast | DCIS | Renal cell carcinoma | 14/846 | 69/8465 | 7.42e-03 | 3.48e-02 | 2.56e-02 | 14 |
hsa0513020 | Cervix | CC | Pathogenic Escherichia coli infection | 63/1267 | 197/8465 | 9.28e-10 | 2.00e-08 | 1.19e-08 | 63 |
hsa0451010 | Cervix | CC | Focal adhesion | 59/1267 | 203/8465 | 1.53e-07 | 1.84e-06 | 1.09e-06 | 59 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PAK2 | SNV | Missense_Mutation | | c.1312G>A | p.Glu438Lys | p.E438K | Q13177 | protein_coding | deleterious(0.02) | probably_damaging(0.995) | TCGA-A2-A0YK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
PAK2 | SNV | Missense_Mutation | | c.1336N>A | p.Glu446Lys | p.E446K | Q13177 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-A2-A25A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Cytoxan | SD |
PAK2 | SNV | Missense_Mutation | | c.103N>G | p.His35Asp | p.H35D | Q13177 | protein_coding | tolerated(0.19) | benign(0.003) | TCGA-AN-A0XN-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
PAK2 | SNV | Missense_Mutation | | c.419N>C | p.Leu140Pro | p.L140P | Q13177 | protein_coding | tolerated(0.08) | possibly_damaging(0.62) | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
PAK2 | SNV | Missense_Mutation | novel | c.241G>A | p.Glu81Lys | p.E81K | Q13177 | protein_coding | tolerated(0.35) | possibly_damaging(0.734) | TCGA-C8-A8HQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PAK2 | SNV | Missense_Mutation | rs774110601 | c.1250N>A | p.Arg417Gln | p.R417Q | Q13177 | protein_coding | tolerated(0.11) | probably_damaging(0.993) | TCGA-E9-A295-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
PAK2 | insertion | In_Frame_Ins | novel | c.627_628insTCTCGCTCTGTCGCC | p.Ser209_His210insSerArgSerValAla | p.S209_H210insSRSVA | Q13177 | protein_coding | | | TCGA-A8-A08F-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | 5-fluorouracil | CR |
PAK2 | insertion | Frame_Shift_Ins | novel | c.566_567insAAGAAGCAAACTTTTTGAAG | p.His189GlnfsTer17 | p.H189Qfs*17 | Q13177 | protein_coding | | | TCGA-A8-A09D-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | CR |
PAK2 | insertion | Frame_Shift_Ins | novel | c.570_571insTTCATAAAGGGCGATAGTCG | p.Lys191PhefsTer15 | p.K191Ffs*15 | Q13177 | protein_coding | | | TCGA-A8-A09D-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | CR |
PAK2 | insertion | Nonsense_Mutation | novel | c.746_747insATGATACACAGTCATTGCTAACAACTAGTACAGTT | p.Tyr249Ter | p.Y249* | Q13177 | protein_coding | | | TCGA-AN-A03X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
5062 | PAK2 | ENZYME, KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME | inhibitor | 310264720 | | |
5062 | PAK2 | ENZYME, KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME | inhibitor | 249565812 | | |
5062 | PAK2 | ENZYME, KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME | inhibitor | 310264719 | | |
5062 | PAK2 | ENZYME, KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME | inhibitor | 329968394 | | |
5062 | PAK2 | ENZYME, KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME | allosteric modulator | 310264717 | | |
5062 | PAK2 | ENZYME, KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME | inhibitor | 310264722 | | |
5062 | PAK2 | ENZYME, KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME | inhibitor | 310264718 | PF-03758309 | |
5062 | PAK2 | ENZYME, KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME | inhibitor | 135652717 | STAUROSPORINE | |